Royce & Associates LP Buys 165,954 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Royce & Associates LP boosted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 15.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,212,286 shares of the medical technology company’s stock after purchasing an additional 165,954 shares during the quarter. Royce & Associates LP’s holdings in Alphatec were worth $6,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Zions Bancorporation N.A. raised its stake in shares of Alphatec by 108.2% during the 3rd quarter. Zions Bancorporation N.A. now owns 173,180 shares of the medical technology company’s stock worth $963,000 after acquiring an additional 89,992 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Alphatec during the third quarter worth $431,000. Entropy Technologies LP lifted its holdings in shares of Alphatec by 14.9% during the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock valued at $120,000 after purchasing an additional 2,800 shares during the last quarter. Atria Investments Inc boosted its position in shares of Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in Alphatec during the 3rd quarter worth $2,057,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Trading Down 5.7 %

NASDAQ ATEC opened at $8.23 on Monday. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a market capitalization of $1.17 billion, a PE ratio of -6.43 and a beta of 1.31. The company has a fifty day moving average of $6.30 and a 200 day moving average of $8.33.

Insider Buying and Selling at Alphatec

In related news, Director David M. Demski bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were purchased at an average cost of $5.67 per share, with a total value of $283,500.00. Following the completion of the acquisition, the director now directly owns 288,441 shares in the company, valued at approximately $1,635,460.47. The trade was a 20.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ATEC shares. Lake Street Capital decreased their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Stifel Nicolaus dropped their target price on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Thursday, October 31st. Morgan Stanley downgraded Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.00.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.